non-small cell lung cancer
Foundation Medicine Monitoring Assays Show Promise for Guiding Lung Cancer Chemo-Immunotherapy
Premium
Investigators showed that patients who are positive for ctDNA at the time of their fourth induction treatment have poorer outcomes and could benefit from new strategies.
AmoyDx, AstraZeneca Partner on HER2 Lung Cancer CDx Development in China
Amoy will develop a companion diagnostic for Enhertu (trastuzumab deruxtecan) under its latest agreement to develop companion diagnostics for AstraZeneca's therapies.
ChromaCode, Protean BioDiagnostics Partner to Launch Lung Cancer Test
The test uses ChromaCode's High Definition PCR multiplexing technology and detects all National Comprehensive Cancer Network recommended variants in less than 24 hours.
Biocartis, Eli Lilly Partner for Spanish NSCLC Biomarker Study
The study aims to establish how Biocartis' Idylla molecular testing platform can eventually be used to improve community-based diagnostic workflows in the US.
Tempus, AstraZeneca Partner to Study NSCLC Biology in GEMINI Trial
Researchers will molecularly profile patients' tumors and track over three years how their tumor biology changes as their disease progresses and they receive treatment.